Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 12/20 | 0.57 |
| ▸ | JAK1 | P23458 | 12/20 | 0.57 |
| ▸ | JAK3 | P52333 | 12/20 | 0.57 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1369630 | 0.91 | JAK3 (0.52) | JAK2JAK1JAK3DGAT1 | |
| SCHEMBL1353887 | 0.86 | JAK2 (0.39) | JAK2JAK1JAK3DGAT1 | |
| SCHEMBL1353886 | 0.85 | CNR2 (0.43) | JAK2JAK1JAK3TTK | |
| SCHEMBL1696870 | 0.85 | DGAT1 (0.40) | JAK2JAK1JAK3DGAT1TTK | |
| SCHEMBL1369418 | 0.84 | JAK2 (0.38) | JAK2JAK1JAK3DGAT1TTK | |
| SCHEMBL2378628 | 0.84 | JAK2 (0.42) | JAK2JAK1JAK3 | |
| SCHEMBL1351068 | 0.84 | DGAT1 (0.40) | JAK2JAK1JAK3DGAT1EGLN1 | |
| SCHEMBL1369633 | 0.83 | JAK2 (0.39) | JAK2JAK1JAK3DGAT1 | |
| SCHEMBL2344237 | 0.81 | DGAT1 (0.38) | JAK2JAK1JAK3DGAT1 | |
| SCHEMBL1368957 | 0.80 | JAK3 (0.58) | JAK2JAK1JAK3DGAT1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | JAK2 3/4885JAK1 5/4885JAK3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.